Aug. 9 Clinical Quick Takes: Lexicon's one-year Zynquista follow-up; plus 89bio and TopiVert

Biomarker data lift Lexicon
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) rose $0.25 (20%) to $1.53 Friday after reporting pooled 52-week follow-up data from two Phase III trials showing

Read the full 267 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE